載入...
Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study
PURPOSE: Although extensive-stage small-cell lung cancer (SCLC) is highly responsive to first-line therapy, virtually all patients develop resistance with short survival. Rovalpituzumab tesirine (Rova-T) is an antibody–drug conjugate targeting delta-like 3 protein (DLL3). This open-label, single-arm...
Na minha lista:
| 發表在: | Clin Cancer Res |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
2019
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7105795/ https://ncbi.nlm.nih.gov/pubmed/31506387 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-19-1133 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|